Neuroleptic malignant syndrome following cardiac surgery: Successful treatment with dantrolene

European Journal of Cardio-thoracic Surgery

Volumn 24, Issue 3, 2003, Pages 458-460

  Mieno, Shigetoshi ^a   Asada, Kunio ^a   Horimoto, Hitoshi ^a   Sasaki, Shinjiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Cardiac surgery; Dantrolene; Neuroleptic malignant syndrome; Neuroleptics

Indexed keywords

CALCIUM; CREATINE KINASE; CREATININE; DANTROLENE; INFUSION FLUID; MYOGLOBIN; UREA; ZOTEPINE;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CYTOPLASM; DISEASE COURSE; DRUG EFFECT; HEART ATRIUM SEPTUM DEFECT; HEART SURGERY; HEMODIALYSIS; HUMAN; HYPERTHERMIA; INFUSION; MALE; MUSCLE RIGIDITY; MYOGLOBINURIA; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SCHIZOPHRENIA; SHIVERING; SIDE EFFECT; SURGICAL TECHNIQUE; SWEATING; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREMOR; UREA NITROGEN BLOOD LEVEL;

DANTROLENE; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; NEUROLEPTIC MALIGNANT SYNDROME; POSTOPERATIVE COMPLICATIONS;

EID: 0043264171     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(03)00332-4     Document Type: Article

References (10)

1. Caroff S.E., Mann S.C. Neuroleptic malignant syndrome. Med Clin North Am. 77:1993;185-202.
2. Shalev A., Hermesh H., Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 50:1989;18-25.
3. Lieberman A., Pasternack P., Colvin S. The neuroleptic malignant syndrome after open heart surgery: successful treatment with bromocriptine. N Y State Med. 87:1987;362-363.
4. Gurrera R.J. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol. 25:2002;183-193.
5. Wilhelmi M., Winterhalter M., Fischer S., Walles T., Zuk J., Struber M., Haverich A. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther. 16:2002;471-475.
6. Haggie J.E. Malignant hyperthermia: considerations for the general surgeon. Can J Surg. 45:2002;369-372.
7. Gerbershagen M.U., Fiege M., Krause T., Agarwal K., Wappler F. Dantrolen: pharmakologische und therapeutische aspekte. Anaethesist. 52:2003;238-245.
8. 31P NMR and freeze fracture studies of sarcoplasmic reticulum membranes from normal and malignant hyperthermic pigs: effect of halothane and dantrolene. Arch Biochem Biophys. 294:1990;154-159.
9. Either A.R., Neft M.S., Slifkin R.F. Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med. 142:1982;601-603.
10. Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 44:2000;261-273.